Fundraising FoxAlwin Capital — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
EdiGeneedigene.comApr 2021 · $62M
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentBioTrack CapitalIDG Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.